A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

Simple item page
dc.contributor.authorKitchens, John W.
dc.contributor.authorKassem, Nawal
dc.contributor.authorWood, William
dc.contributor.authorStone, Thomas W.
dc.contributor.authorIsernhagen, Rick
dc.contributor.authorWood, Edward
dc.contributor.authorHancock, Brad A.
dc.contributor.authorRadovich, Milan
dc.contributor.authorWaymire, Josh
dc.contributor.authorLi, Lang
dc.contributor.authorSchneider, Bryan P.
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2025-04-30T11:43:17Z
dc.date.available2025-04-30T11:43:17Z
dc.date.issued2013
dc.description.abstractPurpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.
dc.eprint.versionFinal published version
dc.identifier.citationKitchens JW, Kassem N, Wood W, et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol. 2013;7:1987-1993. doi:10.2147/OPTH.S39635
dc.identifier.urihttps://hdl.handle.net/1805/47545
dc.language.isoen_US
dc.publisherDove Press
dc.relation.isversionof10.2147/OPTH.S39635
dc.relation.journalClinical Ophthalmology
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectAge related macular degeneration
dc.subjectBevacizumab
dc.subjectComplement factor H (CFH)
dc.subjectRanibizumab
dc.subjectSingle nucleotide polymorphisms
dc.subjectVascular endothelial growth factor
dc.titleA pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kitchens2013Pharmacogenetics-CCBYNC.pdf
Size:
769.65 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works